Follicular Lymphoma CA073-1003 Golseek-4
Study #CA073-1003A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator’s Choice in Participants With Relapsed/Refractory Follicular Lymphoma
Description
The study is designed as a multicenter, randomized, open label Phase 3 study to compate the efficacy and safety of golcado mide in combination with rituximab vs investigator’s choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systematic therapy.
Sponsor: Celgene
Interested in this trial? Email [email protected]
Back To Clinical Trials NCI Database Entry